Total Payments
$57,130
2024 Payments
$6,923
Companies
44
Transactions
402
Medicare Patients
1,061
Medicare Billing
$222,642
Payment Breakdown by Category
Consulting$34,577 (60.5%)
Food & Beverage$11,946 (20.9%)
Other$9,800 (17.2%)
Education$439.70 (0.8%)
Travel$367.89 (0.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $34,577 | 19 | 60.5% |
| Food and Beverage | $11,946 | 367 | 20.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $8,630 | 3 | 15.1% |
| Honoraria | $1,170 | 1 | 2.0% |
| Education | $439.70 | 7 | 0.8% |
| Travel and Lodging | $367.89 | 5 | 0.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $12,501 | 58 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $11,038 | 17 | $0 (2022) |
| Dova Pharmaceuticals | $5,930 | 2 | $0 (2021) |
| Exelixis Inc. | $5,742 | 18 | $0 (2023) |
| Eisai Inc. | $3,694 | 9 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $3,565 | 34 | $0 (2024) |
| Coherus Biosciences Inc. | $2,700 | 1 | $0 (2022) |
| Eli Lilly and Company | $2,300 | 1 | $0 (2021) |
| Rigel Pharmaceuticals, Inc. | $1,689 | 10 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $1,175 | 37 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $6,923 | 78 | AstraZeneca Pharmaceuticals LP ($3,455) |
| 2023 | $6,654 | 96 | Exelixis Inc. ($2,728) |
| 2022 | $8,925 | 39 | Boehringer Ingelheim Pharmaceuticals, Inc. ($3,761) |
| 2021 | $7,034 | 20 | Dova Pharmaceuticals ($3,680) |
| 2020 | $12,589 | 10 | AstraZeneca Pharmaceuticals LP ($7,021) |
| 2019 | $7,823 | 54 | Boehringer Ingelheim Pharmaceuticals, Inc. ($3,603) |
| 2018 | $6,253 | 75 | Boehringer Ingelheim Pharmaceuticals, Inc. ($3,674) |
| 2017 | $929.21 | 30 | Novartis Pharmaceuticals Corporation ($189.90) |
All Payment Transactions
402 individual payment records from CMS Open Payments — Page 1 of 17
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Janssen Biotech, Inc. | TALVEY (Biological), TECVAYLI, DARZALEX | Food and Beverage | In-kind items and services | $30.24 | General |
| Category: Oncology | ||||||
| 12/12/2024 | AstraZeneca Pharmaceuticals LP | Truqap (Drug) | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| Category: Oncology | ||||||
| 12/09/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Food and Beverage | Cash or cash equivalent | $36.16 | General |
| Category: Oncology / Rare Diseases | ||||||
| 12/05/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Food and Beverage | In-kind items and services | $11.66 | General |
| Category: ONCOLOGY | ||||||
| 12/03/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA, BALVERSA | Food and Beverage | In-kind items and services | $30.84 | General |
| Category: Oncology | ||||||
| 11/20/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $35.45 | General |
| Category: Oncology | ||||||
| 11/19/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $20.76 | General |
| Category: Oncology | ||||||
| 11/07/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ALUNBRIG (Drug) | Food and Beverage | In-kind items and services | $17.91 | General |
| Category: ONCOLOGY | ||||||
| 11/06/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Food and Beverage | In-kind items and services | $24.43 | General |
| Category: Genetically Defined Disease | ||||||
| 10/30/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological), TALVEY, DARZALEX | Food and Beverage | In-kind items and services | $28.81 | General |
| Category: Oncology | ||||||
| 10/30/2024 | Takeda Pharmaceuticals U.S.A., Inc. | VPRIV (Biological) | Food and Beverage | In-kind items and services | $26.99 | General |
| Category: GENETIC DISEASE | ||||||
| 10/30/2024 | Takeda Pharmaceuticals U.S.A., Inc. | VPRIV (Biological) | Food and Beverage | In-kind items and services | $1.82 | General |
| Category: GENETIC DISEASE | ||||||
| 10/23/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $29.24 | General |
| Category: ONCOLOGY | ||||||
| 10/02/2024 | Bayer Healthcare Pharmaceuticals Inc. | Stivarga (Drug), Vitrakvi | Food and Beverage | In-kind items and services | $26.66 | General |
| Category: Oncology | ||||||
| 10/01/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| Category: Oncology | ||||||
| 09/24/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Food and Beverage | In-kind items and services | $20.16 | General |
| Category: Genetically Defined Disease | ||||||
| 09/18/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $23.44 | General |
| 09/11/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $28.57 | General |
| Category: ONCOLOGY | ||||||
| 09/04/2024 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $29.20 | General |
| Category: ONCOLOGY | ||||||
| 09/04/2024 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $2.92 | General |
| Category: ONCOLOGY | ||||||
| 08/26/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| Category: Oncology | ||||||
| 08/21/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $41.07 | General |
| 08/14/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA, BALVERSA | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: Oncology | ||||||
| 08/08/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), WELIREG | Food and Beverage | In-kind items and services | $25.88 | General |
| Category: ONCOLOGY | ||||||
| 08/07/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $29.94 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 264 | 595 | $180,308 | $50,828 |
| 2022 | 7 | 277 | 606 | $202,770 | $63,488 |
| 2021 | 7 | 271 | 621 | $226,167 | $65,635 |
| 2020 | 9 | 249 | 555 | $178,438 | $42,691 |
Total Patients
1,061
Total Services
2,377
Medicare Billing
$222,642
Procedure Codes
31
All Medicare Procedures & Services
31 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 112 | 411 | $122,230 | $33,190 | 27.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 25 | 25 | $12,450 | $3,900 | 31.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 20 | 20 | $10,535 | $3,200 | 30.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 21 | 40 | $8,800 | $2,890 | 32.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 22 | 23 | $9,038 | $2,751 | 30.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 35 | 44 | $9,400 | $2,477 | 26.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 16 | 17 | $6,805 | $2,087 | 30.7% |
| 85060 | Blood smear interpretation by physician with written report | Facility | 2023 | 13 | 15 | $1,050 | $332.55 | 31.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 114 | 421 | $120,640 | $37,405 | 31.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 54 | 55 | $29,700 | $9,458 | 31.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 39 | 39 | $22,230 | $6,698 | 30.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 29 | 42 | $18,060 | $5,860 | 32.4% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 13 | 13 | $5,070 | $1,689 | 33.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 17 | 23 | $4,600 | $1,553 | 33.8% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 11 | 13 | $2,470 | $824.74 | 33.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 104 | 438 | $139,722 | $39,266 | 28.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 42 | 42 | $24,780 | $8,010 | 32.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 36 | 36 | $21,888 | $6,139 | 28.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 26 | 35 | $14,945 | $4,803 | 32.1% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 23 | 23 | $11,155 | $3,030 | 27.2% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 20 | 20 | $7,980 | $2,609 | 32.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 20 | 27 | $5,697 | $1,778 | 31.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 86 | 355 | $113,245 | $25,285 | 22.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 22 | 24 | $14,160 | $4,545 | 32.1% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 25 | 33 | $14,091 | $3,288 | 23.3% |
About Dr. Lan Mo, M.D
Dr. Lan Mo, M.D is a Hematology & Oncology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/23/2010. The National Provider Identifier (NPI) number assigned to this provider is 1760786388.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Lan Mo, M.D has received a total of $57,130 in payments from pharmaceutical and medical device companies, with $6,923 received in 2024. These payments were reported across 402 transactions from 44 companies. The most common payment nature is "Consulting Fee" ($34,577).
As a Medicare-enrolled provider, Mo has provided services to 1,061 Medicare beneficiaries, totaling 2,377 services with total Medicare billing of $222,642. Data is available for 4 years (2020–2023), covering 31 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location New York, NY
- Active Since 12/23/2010
- Last Updated 08/11/2014
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1760786388
Products in Payments
- GILOTRIF (Drug) $7,463
- Doptelet (Drug) $5,930
- LYNPARZA (Drug) $4,315
- TAGRISSO (Drug) $3,828
- Lenvima (Drug) $3,678
- Cabometyx (Drug) $2,889
- CABOMETYX (Drug) $2,853
- IMFINZI (Biological) $2,639
- OPDIVO (Biological) $2,124
- Tavalisse (Drug) $1,459
- BRUKINSA (Drug) $650.00
- CALQUENCE (Drug) $628.84
- NINLARO (Drug) $574.38
- Truqap (Drug) $525.00
- KEYTRUDA (Biological) $479.09
- IMFINZI (Drug) $370.97
- PROMACTA (Drug) $328.53
- IMBRUVICA (Drug) $297.14
- JAKAFI (Drug) $279.44
- KISQALI (Drug) $260.56
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in New York
Jeffrey Zwicker, M.d, M.D
Hematology & Oncology — Payments: $1.2M
Hematology & Oncology $1.2M
Manuel Hidalgo Medina, M.d, M.D
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Dr. Ahmed Sawas, M.d, M.D
Hematology & Oncology — Payments: $807,524
Hematology & Oncology $807,524
Ruben Niesvizky, Md, MD
Hematology & Oncology — Payments: $734,512
Hematology & Oncology $734,512
Jeffrey Laurence, Md, MD
Hematology & Oncology — Payments: $706,018
Hematology & Oncology $706,018
Dr. Joshua Sabari, M.d, M.D
Hematology & Oncology — Payments: $603,205
Hematology & Oncology $603,205